PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSaquinavir
Invirase(saquinavir)
Fortovase, Invirase (saquinavir) is a small molecule pharmaceutical. Saquinavir was first approved as Invirase on 1995-12-06. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Saquinavir
Tradename
Company
Number
Date
Products
FORTOVASERocheN-020828 DISCN1997-11-07
1 products, RLD
Hide discontinued
Saquinavir mesylate
Tradename
Company
Number
Date
Products
INVIRASERocheN-020628 DISCN1995-12-06
1 products, RLD
INVIRASERocheN-021785 DISCN2004-12-17
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
inviraseNew Drug Application2010-09-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE01: Saquinavir
HCPCS
Code
Description
S0140
Saquinavir, 200 mg
Clinical
Clinical Trials
93 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2017342391084
Acquired immunodeficiency syndromeD000163EFO_0000765B201753318
InfectionsD007239EFO_0000544——12126
LipodystrophyD008060—E88.1———2—2
Cardiovascular diseasesD002318EFO_0000319I98———1—1
Hiv-associated lipodystrophy syndromeD039682EFO_1001348————1—1
Healthy volunteers/patients——————1—1
Renal insufficiencyD051437—N19———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aids-related complexD000386EFO_0007137B20—41——5
HivD006678—O98.7——1—23
Directly observed therapyD023801————1——1
Kidney diseasesD007674EFO_0003086N08——1——1
Aids-associated nephropathyD016263EFO_0007313———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D015497———1———1
SarcomaD012509———1———1
Kaposi sarcomaD012514—C46—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD000081029——1————1
PregnancyD011247EFO_0002950Z33.11————1
Substance-related disordersD019966EFO_0003890F131————1
Adolescent behaviorD000294——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD003141——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSaquinavir
INNsaquinavir
Description
Saquinavir is an aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease. It has a role as a HIV protease inhibitor and an antiviral drug. It is a member of quinolines and a L-asparagine derivative.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
Identifiers
PDB—
CAS-ID127779-20-8
RxCUI—
ChEMBL IDCHEMBL114
ChEBI ID63621
PubChem CID441243
DrugBankDB01232
UNII IDL3JE09KZ2F (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Saquinavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,077 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,634 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use